Human and animal hepatocytes in vitro with extrapolation in vivo.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Chemico-Biological Interactions

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CBI.2004.09.003PMID 15522264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of protein tyrosine kinases in CYP1A1 induction by omeprazole and thiabendazole in rat hepatocytes.

  2004cited by this paper
• Quantitative structure toxicity relationships for catechols in isolated rat hepatocytes.

  2004cited by this paper
• Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes.

  2004cited by this paper
• Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase*

  2003cited by this paper
• Modulating carbonyl cytotoxicity in intact rat hepatocytes by inhibiting carbonyl metabolizing enzymes. II. Aromatic aldehydes.

  2003cited by this paper
• Retention of transporter activities in cryopreserved, isolated rat hepatocytes.

  2003cited by this paper
• Quantitative structure toxicity relationships for phenols in isolated rat hepatocytes.

  2003cited by this paper
• Phase II in vitro metabolism of 3-methylindole metabolites in porcine liver

  2003cited by this paper
• Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes.

  2003cited by this paper
• Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.

  2003cited by this paper
• Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

  2003cited by this paper
• Serotonin (5-hydroxytryptamine) glucuronidation in vitro : assay development, human liver microsome activities and species differences

  2003cited by this paper
• Modulating carbonyl cytotoxicity in intact rat hepatocytes by inhibiting carbonyl-metabolizing enzymes. I. Aliphatic alkenals.

  2003cited by this paper
• The Liverbeads as a tool for the comet assay.

  2002cited by this paper
• Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice.

  2002cited by this paper
• Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.

  2002cited by this paper
• Timing of new black box warnings and withdrawals for prescription medications.

  2002cited by this paper
• Identification of glutathione conjugates of troglitazone in human hepatocytes.

  2002cited by this paper
• Metabolic activation of 4-hydroxyanisole by isolated rat hepatocytes.

  2002cited by this paper
• An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids

  2001cited by this paper
• Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects.

  2001cited by this paper
• A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation.

  2001cited by this paper
• Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2.

  2001cited by this paper
• Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance.

  2001cited by this paper
• Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer.

  2001cited by this paper
• Using DNA and hemoglobin adducts to improve the risk assessment of butadiene.

  2001cited by this paper
• Species differences in the metabolism of olefins: implications for risk assessment.

  2001cited by this paper
• Paracetamol (Acetaminophen)-Induced Toxicity: Molecular and Biochemical Mechanisms, Analogues and Protective Approaches

  2001cited by this paper
• Lysosomal oxidative stress cytotoxicity induced by nitrofurantoin redox cycling in hepatocytes.

  2001cited by this paper
• Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.

  2001cited by this paper
• Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog.

  2001cited by this paper
• Bioactivation and cytotoxicity of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123) in isolated rat hepatocytes.

  2001cited by this paper
• Cytochrome P450 2E1 metabolically activates propargyl alcohol: propiolaldehyde-induced hepatocyte cytotoxicity.

  2001cited by this paper
• Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.

  2001cited by this paper
• Arylamine N-acetyltransferases - of mice, men and microorganisms.

  2001cited by this paper
• o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin.

  2000cited by this paper
• Response of urinary lipophilic aldehydes and related carbonyl compounds to factors that stimulate lipid peroxidation in vivo

  2000cited by this paper
• The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures.

  2000cited by this paper
• CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers.

  2000cited by this paper
• o-HYDROXYPHENYLACETALDEHYDE IS A HEPATOTOXIC METABOLITE OF COUMARIN 1

  2000cited by this paper
• Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man

  2000cited by this paper
• The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.

  2000cited by this paper
• Urinary aldehydes as indicators of lipid peroxidation in vivo.

  2000cited by this paper
• Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms.

  2000cited by this paper
• CRYOPRESERVED PRIMARY HEPATOCYTES AS A CONSTANTLY AVAILABLE IN VITRO MODEL FOR THE EVALUATION OF HUMAN AND ANIMAL DRUG METABOLISM AND ENZYME INDUCTION*

  2000cited by this paper
• The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution

  2000cited by this paper
• Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.

  1999cited by this paper
• Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes.

  1999cited by this paper
• Role of the cellular redox state in modulating acute ethanol toxicity in isolated hepatocytes.

  1999cited by this paper
• Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel.

  1999cited by this paper
• L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats.

  1999cited by this paper
• Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications

  1999cited by this paper
• Species and sex differences in expression of flavin-containing monooxygenase form 3 in liver and kidney microsomes.

  1999cited by this paper
• Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity.

  1999cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• Spontaneous chemiluminescence production, lipid peroxidation, and covalent binding in rat hepatocytes exposed to acetaminophen.

  1998cited by this paper
• Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells

  1998cited by this paper
• Evaluation of urinary biomarkers for radical-induced liver damage in rats treated with carbon tetrachloride.

  1998cited by this paper
• Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes.

  1997cited by this paper
• UDP-glucose:glycoprotein glucosyltransferase associates with endoplasmic reticulum chaperones and its activity is decreased in vivo by the inhalation anesthetic halothane.

  1997cited by this paper
• Molecular cloning of cDNA for guinea pig CYP1A2 comparison with guinea pig CYP1A1.

  1997cited by this paper
• Phenylenediamine induced hepatocyte cytotoxicity redox. Cycling mediated oxidative stress without oxygen activation.

  1997cited by this paper
• Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes.

  1997cited by this paper
• Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity.

  1997cited by this paper
• Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species.

  1997cited by this paper
• Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans

  1997cited by this paper
• Cytochrome P4502C11 is a target of diclofenac covalent binding in rats.

  1997cited by this paper
• Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes.

  1997cited by this paper
• Influence of the halogen-substituent pattern of fluoronitrobenzenes on their biotransformation and capacity to induce methemoglobinemia.

  1996cited by this paper
• The involvement of cytochrome P4502E1 in 2-bromoethanol-induced hepatocyte cytotoxicity.

  1996cited by this paper
• Metabolism and toxicity of coumarin on cultured human, rat, mouse and rabbit hepatocytes

  1996cited by this paper
• The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype

  1995cited by this paper
• Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats.

  1995cited by this paper
• Formation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro.

  1994cited by this paper
• Molecular mechanisms of nitrofurantoin-induced hepatocyte toxicity in aerobic versus hypoxic conditions.

  1993cited by this paper
• Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes.

  1993cited by this paper
• Oxidative stress in cultured hepatocytes exposed to acetaminophen.

  1993cited by this paper
• Nitrofurantoin-induced pulmonary toxicity. In vivo evidence for oxidative stress-mediated mechanisms.

  1992cited by this paper
• Isolation and culturing of hepatocytes from human livers

  1992cited by this paper
• Mitochondrial oxidation of p-phenylenediamine derivatives in vitro: structure-activity relationships and correlation with myotoxic activity in vivo.

  1992cited by this paper
• Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for Humans a

  1992cited by this paper
• Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450.

  1992cited by this paper
• NADH-dependent reductive stress and ferritin-bound iron in allyl alcohol-induced lipid peroxidation in vivo: the protective effect of vitamin E.

  1992cited by this paper
• Molecular mechanisms of quinone cytotoxicity.

  1991cited by this paper
• Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver.

  1991cited by this paper
• Prevention of nitrofurantoin-induced cytotoxicity in isolated hepatocytes by fructose.

  1991cited by this paper
• Toxicity of nitrobenzene compounds towards isolated hepatocytes: dependence on reduction potential.

  1990cited by this paper
• Molecular mechanisms for bromotrichloromethane cytotoxicity in isolated rat hepatocytes.

  1990cited by this paper
• Reaction of glutathione with a free radical metabolite of carbon tetrachloride.

  1990cited by this paper
• Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant.

  1990cited by this paper
• Metabolism and cytotoxicity of acetaminophen in hepatocyte cultures from rat, rabbit, dog, and monkey.

  1990cited by this paper
• The role of oxidative biotransformation of halothane in the guinea pig model of halothane-associated hepatotoxicity.

  1989cited by this paper
• 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines.

  1989cited by this paper
• Diaziquone-induced cytotoxicity in isolated rat hepatocytes.

  1989cited by this paper
• Allyl alcohol- and acrolein-induced toxicity in isolated rat hepatocytes.

  1989cited by this paper
• The Role of Oxidative Biotransformation of Halothane in the Guinea Pig Model of Halothane-associated Hepatotoxicity

  1988cited by this paper
• In vivo radical trapping and biliary secretion of radical adducts of carbon tetrachloride-derived free radical metabolites.

  1988cited by this paper
• The role of acrolein in allyl alcohol-induced lipid peroxidation and liver cell damage in mice.

  1987cited by this paper
• Species differences in enzymes controlling reactive epoxides.

  1987cited by this paper
• Comparison of cytochrome P-450 content and activities in liver microsomes of seven animal species, including man.

  1986cited by this paper

• Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury

  2025cites this paper
• Multicellular hepatic in vitro models using NANOSTACKSTM: human-relevant models for drug response prediction

  2025cites this paper
• Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches.

  2024cites this paper
• Multicellular, fluid flow-inclusive hepatic in vitro models using NANOSTACKSTM: a human-relevant model for drug response prediction

  2024cites this paper
• Evaluation of in vitro toxicity information for zebrafish as a promising alternative for chemical hazard and risk assessment.

  2023cites this paper
• Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol

  2023cites this paper
• Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery

  2023cites this paper
• In Vitro Models for Studying Chronic Drug-Induced Liver Injury

  2022cites this paper
• Liver-on-a-Chip devices: The Pros and Cons of Complexity.

  2022cites this paper
• Effect of cytochrome P450 inhibition on toxicity of diclofenac in chickens: Unravelling toxicity in Gyps vultures

  2022cites this paper
• Carbon Black CB-EDA Nanoparticles in Hepatocytes: Changes in the Oxidative Stress Pathway

  2022cites this paper
• N-acetyltransferase 2 acetylator genotype-dependent N-acetylation and toxicity of the arylamine carcinogen β-naphthylamine in cryopreserved human hepatocytes

  2022cites this paper
• Hepatocyte cultures: From collagen gel sandwiches to microfluidic devices with integrated biosensors

  2021cites this paper
• Induced pluripotent stem cells in liver disease

  2021cites this paper
• Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction

  2021cites this paper
• Use of 3D Human Liver Organoids to Predict Drug-Induced Phospholipidosis

  2020cites this paper
• Predicting the Acute Liver Toxicity of Aflatoxin B1 in Rats and Humans by an In Vitro–In Silico Testing Strategy

  2020cites this paper
• Pluripotent human stem cells

  2020cites this paper
• Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury.

  2018cites this paper
• In vitro and cellular systems for the characterization of bioactivating and inactivating drug metabolizing enzymes in adverse drug reactions: Insights into amodiaquine idiosyncratic toxicity

  2018cites this paper
• Phase I and phase II metabolite identification of rutaecarpine in freshly isolated hepatocytes from male Sprague–Dawley rats

  2017cites this paper
• Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models

  2017cites this paper
• Pluripotent Human Stem Cells A Novel Tool in Drug Discovery

  2017cites this paper
• Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing

  2017cites this paper
• Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.

  2016cites this paper
• In vitro toxicity testing using human pluripotent stem cell derivatives

  2016cites this paper
• Concise Review: Updated Advances and Current Challenges in Cell Therapy for Inborn Liver Metabolic Defects

  2016cites this paper
• A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury

  2016cites this paper
• Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening

  2016cites this paper
• Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.

  2016cites this paper
• Small‐Molecule Safety Lead Optimization

  2016cites this paper
• Metabolic activation and drug‐induced liver injury: in vitro approaches for the safety risk assessment of new drugs

  2016cites this paper
• Acetylated starch nanocrystals: Preparation and antitumor drug delivery study.

  2016cites this paper
• Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOCTM) System

  2015cites this paper
• LC‐MS untargeted metabolomic analysis of drug‐induced hepatotoxicity in HepG2 cells

  2015cites this paper
• 3D Cultivation Techniques for Primary Human Hepatocytes

  2015cites this paper
• Hepatocyte-Based Metabolism, Drug–Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition

  2015cites this paper
• Evaluation of Drug-Induced Liver Injury in an In Vitro Oxidative Stress Inflammation System

  2014influential citation
• Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity

  2014cites this paper
• Evaluation of Azathioprine-Induced Cytotoxicity in an In Vitro Rat Hepatocyte System

  2014cites this paper
• Drug safety testing paradigm, current progress and future challenges: an overview

  2014cites this paper
• Competency of different cell models to predict human hepatotoxic drugs

  2014influential citation
• A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model

  2014cites this paper
• Flutamide-Induced Cytotoxicity and Oxidative Stress in an In Vitro Rat Hepatocyte System

  2014cites this paper
• Biomarkers and human hepatocytes.

  2014cites this paper
• In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.

  2014cites this paper
• Cell-based models to predict human hepatotoxicity of drugs

  2014cites this paper
• In vitro Evaluation of the Cytotoxicity of Starch from Curcuma comosa Rhizomes

  2014cites this paper
• Drug‐Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools

  2014cites this paper
• A Novel Lipid-based Nanotechnology Platform For Biomedical Imaging And Breast Cancer Chemotherapy

  2013cites this paper
• Modeling Phospholipidosis Induction: Reliability and Warnings

  2013cites this paper
• Multifunctional terpolymeric MRI contrast agent with superior signal enhancement in blood and tumor.

  2013cites this paper
• Novel Polysaccharide Based Polymers and Nanoparticles for Controlled Drug Delivery and Biomedical Imaging

  2012cites this paper
• pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.

  2012cites this paper
• New Models for the In Vitro Study of Liver Toxicity: 3D Culture Systems and the Role of Bioreactors

  2012cites this paper
• Development of optimised cryopreservation protocol for encapsulated liver cell spheroids : towards delivery of a bioartificial liver

  2012cites this paper
• The Continuum of Health Risk Assessments

  2012cites this paper
• Polysaccharide functionalized magnetic nanoparticles for cell labeling and tracking: A new three-dimensional cell-array system for toxicity testing

  2012cites this paper
• Merging bioreactor technology with 3D hepatocyte-fibroblast culturing approaches: Improved in vitro models for toxicological applications.

  2011cites this paper
• Toxicogenomics and Animal Alternatives

  2011cites this paper
• LIVER TISSUE MODEL FOR DRUG TOXICITY SCREENING

  2011cites this paper
• Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue.

  2011cites this paper
• Critical Human Hepatocyte-Based In Vitro Assays for the Evaluation of Adverse Drug Effects

  2011cites this paper
• Accelerated Cytotoxicity Mechanism Screening of 4-Aminobiphenyl in an in vitro Hepatocyte Inflammation Model

  2011cites this paper
• Pluripotent Human Stem Cells

  2010cites this paper
• A PROTEOMIC STUDY OF OXIDATIVE STRESS IN ALCOHOLIC LIVER DISEASE

  2010cites this paper
• Chemical and biochemical aspects of drug-induced liver injury

  2010cites this paper
• In vitro toxicity assessment of chitosan nanoparticles

  2010cites this paper
• Comprehensive assessment of ADMET risks in drug discovery.

  2009cites this paper
• Gel entrapment culture of rat hepatocytes for investigation of tetracycline-induced toxicity.

  2009cites this paper
• Liver proteome analysis in a rodent model of alcoholic steatosis.

  2009cites this paper
• Liver tissue engineering in the evaluation of drug safety

  2009cites this paper
• Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and Mechanisms

  2009cites this paper
• Hepatocyte cytotoxicity induced by hydroperoxide (oxidative stress model) or glyoxal (carbonylation model): prevention by bioactive nut extracts or catechins.

  2009cites this paper
• Genotoxic effects of wastewater from an oncological ward.

  2009cites this paper
• Pathway analysis tools and toxicogenomics reference databases for risk assessment.

  2008cites this paper
• Rifampicin exacerbates isoniazid‐induced toxicity in human but not in rat hepatocytes in tissue‐like cultures

  2008cites this paper
• Arecoline-induced growth arrest and p21WAF1 expression are dependent on p53 in rat hepatocytes.

  2008cites this paper
• Effects of glycyrrhizic acid on cocklebur‐induced hepatotoxicity in rat and human hepatocytes

  2008cites this paper
• Mechanisms of drug-induced oxidative stress in the hepatocyte inflammation model.

  2008cites this paper
• Développement et caractérisation d'une puce à cellules pour le criblage d'agents toxiques

  2008cites this paper
• Maximising use ofin vitroADMET tools to predictin vivobioavailability and safety

  2007cites this paper
• Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety

  2007cites this paper
• Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver

  2007cites this paper
• Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies

  2007cites this paper
• Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.

  2007cites this paper
• Improving Decision-Making in Drug Development Using In Vitro Toxicology Screening

  2007cites this paper
• Benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide (DDAB), two common quaternary ammonium compounds, cause genotoxic effects in mammalian and plant cells at environmentally relevant concentrations.

  2007cites this paper
• Folate metabolism in the human colon: cellular responses identified through in vitro studies

  2006cites this paper
• Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.

  2006cites this paper
• ‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective

  2006cites this paper
• Stem cells, immortalized cells and primary cells in ADMET assays.

  2006cites this paper
• Predictive value of in vitro safety studies.

  2006cites this paper
• Functional hepatocyte-like cells derived from mouse embryonic stem cells: a novel in vitro hepatotoxicity model for drug screening.

  2006cites this paper
• Toxicological assessment of industrial solvents using human cell bioassays: assessment of short-term cytotoxicity and long-term genotoxicity potential

  2006cites this paper
• Acetaminophen-induced hepatotoxicity of gel entrapped rat hepatocytes in hollow fibers.

  2006cites this paper
• GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING

  2006cites this paper
• Formation, morphology and function of a 3D hepatocyte-hepatic stellate cell co-culture system

  2006cites this paper
• The smart Petri dish: a nanostructured photonic crystal for real-time monitoring of living cells.

  2006cites this paper
• Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

  2005cites this paper